Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivo... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
0
Authors
Jedd Wolchok
28 more
Jedd Wolchok
•
Vanna Chiarion‐Sileni
26 more
•
F. Hodi
Published
November 24, 2021
Paper
Conversation
0
Reviews
0
Bounties
0
Loading PDF viewer…
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Journal of Clinical Oncology
Topics
Medicine
Cancer Oncology
Internal Medicine
Molecular Biology
Nivolumab
Show all topics
DOI
10.1200/jco.21.02229
License
CC-BY
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
Journal of Clinical Oncology
Topics
Medicine
Cancer Oncology
Internal Medicine
Molecular Biology
Nivolumab
Show all topics
DOI
10.1200/jco.21.02229
License
CC-BY
Other Formats
PDF
